APVO - Aptevo: Positive Early Stage Data Makes This Highly Interesting
- Aptevo went up hugely on positive phase 1 data in AML.
- The company develops bispecific antibodies against cancer.
- Although early stage, this is a definite candidate for my watchlist.
For further details see:
Aptevo: Positive Early Stage Data Makes This Highly Interesting